Carregant...
Burosumab: A new drug to treat hypophosphatemic rickets
Burosumab (KRN23) is a fully human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic rickets. A report enclosed in this letter gives a brief review of current knowledge on buro...
Guardat en:
| Publicat a: | Sudan J Paediatr |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Discover Publishing Group
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5845463/ https://ncbi.nlm.nih.gov/pubmed/29545670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.24911/SJP.2017.2.11 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|